Search hospitals

>

New Brunswick

>

SAINT JOHN

Regional Health Authority B, Zone 2

Claim this profile

SAINT JOHN, New Brunswick E2L 4L2

Conducts research for Lung Cancer

Conducts research for Multiple Myeloma

Conducts research for Cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Lymphoma

11 reported clinical trials

2 medical researchers

Photo of Regional Health Authority B, Zone 2 in SAINT JOHNPhoto of Regional Health Authority B, Zone 2 in SAINT JOHNPhoto of Regional Health Authority B, Zone 2 in SAINT JOHN

Summary

Regional Health Authority B, Zone 2 is a medical facility located in SAINT JOHN, New Brunswick. This center is recognized for care of Lung Cancer, Multiple Myeloma, Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Regional Health Authority B, Zone 2 is involved with conducting 11 clinical trials across 27 conditions. There are 2 research doctors associated with this hospital, such as Anthony J. Reiman and Margot J. Burnell.

Area of expertise

1

Lung Cancer

Regional Health Authority B, Zone 2 has run 3 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II
2

Multiple Myeloma

Regional Health Authority B, Zone 2 has run 2 trials for Multiple Myeloma.

Top PIs

Anthony J. Reiman

Regional Health Authority B, Zone 2

6 years of reported clinical research

Studies Multiple Myeloma
Studies Sleep Disorder
3 reported clinical trials
7 drugs studied

Margot J. Burnell

Regional Health Authority B, Zone 2

5 years of reported clinical research

Studies Breast Cancer
Studies Breast cancer
2 reported clinical trials
4 drugs studied

Clinical Trials running at Regional Health Authority B, Zone 2

Multiple Myeloma

Chronic Lymphocytic Leukemia

Cancer

Lymphoma

Image of trial facility.

Daratumumab

for Multiple Myeloma

Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?

Recruiting

2 awards

Phase 3

Similar Hospitals nearby

Select from list below to view details

Frequently asked questions

What kind of research happens at Regional Health Authority B, Zone 2?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.